Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
Wenzelburger
Roland
R
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology*; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*
D000978:Antiparkinson Agents; D015259:Dopamine Agents